Scientists at Uppsala University have invented a new blood test technology; CDV-21 that currently defy all odds by making possible simultaneous measuring of 21 biomarkers for cardiovascular disease. Aside the major possibilities presented by this new instrument, it is also recorded to have great precision.
According to the scientific paper which was published in journal PLOS One, the instrument would help improve the prediction of cardiovascular complications and also facilitate more personalized treatment by making it easier to monitor the effects of treatment.
How does CDV-21 work to predict cardiovascular disease?
As a result of the analyses of 368 proteins in blood samples from over 10,000 patients, the researchers have identified 21 circulating proteins (CVD-21 panel) that can be used as biomarkers – a principle behind the diagnostic action of this new instrument.
Also, the authors claim that the biomarkers reflect functional and cellular abnormalities that result in development of cardiovascular disease as well as the benefits and risks associated with different treatment methods.
Additionally, the CVD-21 instrument has an advantage of measuring protein contents down to very low concentrations using molecular biology technology known as Proximity Extension Assay (PEA), which has been developed by researchers in Uppsala.
To ascertain accuracy, the information from the CVD-21 instrument has been evaluated using blood samples and clinical information from 4,224 patients with chronic coronary disease.This has paved way for Uppsala University to collaborate with Olink Proteomics and SciLifeLab to manufacture the instrument.